Form 8-K - Current report:
SEC Accession No. 0001628280-24-009548
Filing Date
2024-03-07
Accepted
2024-03-07 08:44:19
Documents
16
Period of Report
2024-03-05
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K frtx-20240305.htm   iXBRL 8-K 27213
2 EX-10.1 a202403058kex101.htm EX-10.1 14985
6 frtx-20240305_g1.jpg GRAPHIC 29102
  Complete submission text file 0001628280-24-009548.txt   232243

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT frtx-20240305.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT frtx-20240305_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT frtx-20240305_pre.xml EX-101.PRE 13052
17 EXTRACTED XBRL INSTANCE DOCUMENT frtx-20240305_htm.xml XML 2544
Mailing Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301
Business Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301 (720) 505-4755
Fresh Tracks Therapeutics, Inc. (Filer) CIK: 0000819050 (see all company filings)

EIN.: 930948554 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21088 | Film No.: 24728268
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)